Comparative analysis of clinical efficacy of atorvastatin with different doses and combined with ezetimibe in the treatment of patients with acute ischemic stroke

Comparative analysis of clinical efficacy of atorvastatin with different doses and combined with ezetimibe in the treatment of patients with acute ischemic stroke - CACEADDCETAIS

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300078970

Enrollment

Unknown

Registered

2023-12-21

Start date

2023-12-31

Completion date

Unknown

Last updated

2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

A:Atorvastatin 20mg/ day

B:Atorvastatin 40mg/ day

C:Atorvastatin was given 80mg immediately after admission and 20mg/ day thereafter

D:Atorvastatin was given 80mg immediately after admission and 40mg/ day thereafter

E:Atorvastatin was given 80mg immediately after admission, followed by atorvastatin 40mg/ day + ezetimibe 10mg/ day

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: ? Acute cerebral infarction. ? Age 18-80 years old. ? Onset <24 h.

Exclusion criteria

Exclusion criteria: ? Combined with serious cardiopulmonary, liver and kidney dysfunction, serious blood system diseases; ? Patients who are allergic to statins or ezetimibe or can not tolerate it. ? Take lipid-lowering drugs 2 weeks before onset. ? Suffering from systemic immune system diseases.

Design outcomes

Primary

Measure	Time frame
early neurological deterioration;	—

Secondary

Measure	Time frame
neural functional recovery;Recurrence of cerebrovascular disease;blood fat;safety;	—

Countries

China

Contacts

Public ContactYongiu Li

Tangshan GongRen Hospital

yongqiuli1965@163.com+86 138 3282 5715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026